Literature DB >> 18026115

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Matthias T Stephan1, Vladimir Ponomarev, Renier J Brentjens, Alex H Chang, Konstantin V Dobrenkov, Glenn Heller, Michel Sadelain.   

Abstract

To reject tumors, T cells must overcome poor tumor immunogenicity and an adverse tumor microenvironment. Providing agonistic costimulatory signals to tumor-infiltrating T cells to augment T cell function remains a challenge for the implementation of safe and effective immunotherapy. We hypothesized that T cells overexpressing selected costimulatory ligands could serve as cellular vehicles mediating powerful, yet constrained, anatomically targeted costimulation. Here, we show that primary human T cells expressing CD80 and 4-1BB ligand (4-1BBL) vigorously respond to tumor cells lacking costimulatory ligands and provoke potent rejection of large, systemic tumors in immunodeficient mice. In addition to showing costimulation of bystander T cells (transcostimulation), we show the effect of CD80 and 4-1BBL binding to their respective receptors in the immunological synapse of isolated single cells (autocostimulation). This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026115     DOI: 10.1038/nm1676

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  130 in total

1.  Quantitative analysis of cell tracing by in vivo imaging system.

Authors:  Junmeng Zheng; Lijun Xu; Hongmin Zhou; Weina Zhang; Zhonghua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

2.  Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Authors:  Juan F Vera; Lara J Brenner; Ulrike Gerdemann; Minhtran C Ngo; Uluhan Sili; Hao Liu; John Wilson; Gianpietro Dotti; Helen E Heslop; Ann M Leen; Cliona M Rooney
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 5.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

Review 9.  The role of B7 family molecules in hematologic malignancy.

Authors:  Paul Greaves; John G Gribben
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 10.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.